Bajaj Finserv Healthcare Fund

A Sectoral/Thematic Fund scheme from Bajaj Finserv Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF0QA701AB9).

NAV ₹12.4590 on 16 November 2026.

Expense ratio

Total expense ratio 0.90% a year for the Direct · Growth plan, as AMFI published it on 29 October 2026: base expense ratio 0.66%, brokerage 0.04%, transaction costs 0.00%, statutory levies including GST 0.20%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year23.0%13.7%-10.9%1.171.22

Too little NAV history for the 3, 5, 10-year figures.

Not ranked in its category: too few comparable funds have the history to rank against.

Largest holdings

Top 10 (September 2026 disclosure). Company shares make up 95.6% of the portfolio.

  1. Divi's Laboratories Limited — 9.75%
  2. Sun Pharmaceutical Industries Limited — 8.96%
  3. Piramal Pharma Limited — 6.36%
  4. Rubicon Research Limited — 6.08%
  5. Aurobindo Pharma Limited — 6.03%
  6. Apollo Hospitals Enterprise Limited — 5.51%
  7. Torrent Pharmaceuticals Limited — 4.78%
  8. Emcure Pharmaceuticals Limited — 4.03%
  9. Laurus Labs Limited — 3.91%
  10. Neuland Laboratories Limited — 3.82%

Plans

Other funds in Sectoral/Thematic Fund

All 257 funds in Sectoral/Thematic Fund · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.